Drug intelligence / Profile preview

PMS-003

Development stage: Preclinical
Lead developer: Qingdao Primedicine Pharmaceutical
Modality: Small Molecules

Overview

PMS-003 is a small molecule inhibitor of Sterol Regulatory Element-Binding Protein 1 (SREBP-1) currently in preclinical development by Qingdao Primedicine Pharmaceutical. SREBP-1 is a key transcription factor that regulates the expression of genes involved in lipid biosynthesis, including fatty acids and triglycerides. By inhibiting SREBP-1, PMS-003 aims to reduce excessive lipogenesis, which is a contributing factor in the pathogenesis of acne (via sebum production) and obesity (via fat accumulation). The drug is being investigated for its potential to modulate metabolic pathways associated with these conditions.

Targets

SREBP-1 / SREBF1 (SREBP-1)

Beyond the preview

Go deeper on PMS-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMS-003.

Explore the full profile